TVTX Travere Therapeutics (TVTX) Q2 FY26 earnings call
Travere Therapeutics delivered exceptional Q2 FY26 results, driven by strong commercial momentum for FILSPARI in both IgA nephropathy and a highly successful early launch in FSGS. The company is also advancing its pipeline with pegtibatinase in Phase III and the strategic addition of civorebrutinib, positioning it for sustained long-term growth in rare kidney diseases. The balance sheet was strengthened through a convertible note refinancing, supporting continued investment in key programs.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
TVTX operating KPIs by quarter
| KPI | Mar 2026 Q1 FY26 | This call Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| New patient start forms FILSPARI | 993The first quarter marked the highest demand to date as we received 993 new patient [ start forms ], reflecting continued expansion among new prescribers and deepening utilization across established accounts.Source: earnings call transcript | 2,000+Their efforts resulted in record FILSPARI demand with over 2,000 new patient start forms across IgA nephropathy and FSGS and record US revenue of more than $141 million for the quarter.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.